<DOC>
	<DOCNO>NCT02757755</DOCNO>
	<brief_summary>This study examine safety ascend dos AB-SA01 topically apply intact skin healthy adult .</brief_summary>
	<brief_title>Ascending Dose Study Safety AB-SA01 When Topically Applied Intact Skin Healthy Adults</brief_title>
	<detailed_description>AB-SA01 consist three bacteriophage ( virus ) target Staphylococcus aureus bacteria . The safety AB-SA01 assess topically administer daily volar aspect forearm dose 10^8 plaque form unit ( PFU ) per phage 3 consecutive day , dose 10^9 plaque form unit ( PFU ) per phage 3 consecutive day . Both AB-SA01 placebo administer subject provide his/her control evaluation skin reaction . The right left placement placebo randomize double-blinded .</detailed_description>
	<criteria>1 . Male female , 18 60 year age , inclusive , time first treatment 2 . Willing able sign inform consent adhere study schedule 3 . Healthy subject determine principal investigator designee via medical history clinical examination enrollment study 4 . Normal skin volar aspect forearm , determine principal investigator designee via examination 5 . If female , subject pregnant breastfeeding negative urine pregnancy test screening , prior receive first study treatment 6 . If female childbearing potential , subject agrees use adequate contraception screening , throughout study period , 30 day completion treatment . 7 . If male , subject female partner childbearing potential must agree use adequate contraception screening , throughout study period , 30 day completion treatment 1 . Any past use bacteriophage product , plan use time screen entire study period 2 . Planned participation another clinical trial and/or use product investigational , drug , biologic device , within 30 day precede screen entire study period 3 . Skin lesion , chronic skin condition , scar tattoo placement , establish skin examination enrollment study would interfere study treatment . 4 . Chronic administration ( defined 14 day total past 6 month ) immunosuppressant immunemodifying drug within 6 month prior first study treatment 5 . Chronic administration topical steroid volar aspect forearm ( define 14 day total 6 month prior first study treatment ) 6 . Any prohibited medication treatment 7 . Any confirmed suspected immunosuppressive immunodeficient condition base medical history , physical examination , screen serology ( HIV , HbsAg , antiHCV ) 8 . History congenital hereditary immunodeficiency 9 . History severe allergic reaction hypersensitivity ( anaphylaxis ) 10 . History allergic reaction irritant contact dermatitis due wound dressing ( eg , adhesive tape , bandage , gauze ) 11 . History allergic reaction castor oil 12 . Acute disease and/or fever time study treatment 13 . Acute chronic , clinically significant pulmonary , cardiovascular , neurologic , hepatic , renal functional abnormality determine medical history , physical examination , laboratory screening test 14 . Screening lab result Grade 2 high abnormality clinically significant Grade 1 abnormality , determine Common Terminology Criteria Adverse Events ( CTCAE ) . 15 . Administration immunoglobulins and/or blood product within 3 month precede first study treatment plan administration study period 16 . Recent ( within 12 month prior screen ) history chronic alcohol abuse , define history ethanol consumption average &gt; 40 g/day woman 60 g/day men least 12 month prior Baseline . 17 . Recent ( within 12 month prior screen ) history illicit drug abuse 18 . Inability comply study requirement restriction 19 . Any reason , consider principal investigator designee , preclude subject involvement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>